Jaguar Health declares dividend and sets five-for-one conversion for Jaguar Health stock

Published on 10/14/2026 at 00:51 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Payment is scheduled for October 15, 2026. For Jaguar Health stock this means a five-for-one conversion capped at 11,625,000 shares in total.

Dividend dates and dilution math

Jaguar Health announced the Series R dividend on October 2, 2026, with a five-for-one conversion ratio.
The dividend payment is scheduled for October 15, 2026.
The conversion is capped at 11,625,000 common shares and 19.99 percent beneficial ownership.

Jaguar Health, biotechnology, special dividend, dilution risk, Nasdaq, Illustration mit AI erstellt.

Jaguar Health declared a special stock dividend and set a five-for-one conversion for Jaguar Health stock on October 2, 2026. The Series R preferred shares are scheduled to convert into common shares on November 2, 2026, creating a clear dilution issue alongside the shareholder benefit.

Three dates define the plan

On September 29, 2026, Jaguar said preliminary crofelemer study results had been accepted for presentation at the American College of Gastroenterology meeting, which ran through October 14, 2026. The separate controlled Phase 2 trial is expected to produce results in the second half of 2027, according to Jaguar Health.

On October 2, 2026, the company announced one Series R preferred share for each eligible common share and certain warrants. The payment date is October 15, 2026, while each preferred share is scheduled to convert into five common shares on November 2, 2026, according to Jaguar Health.

On October 5, 2026, the filed terms put the maximum conversion at 11,625,000 common shares and limited beneficial ownership to 19.99 percent. The same filing states that royalty payments tied to two USD 12.0 million royalty interests move to January 1, 2027, with a monthly payment floor of USD 750,000, according to StockTitan.

What does the conversion mean for dilution?

The arithmetic is material. The filing describes an illustration in which 2,138,712 common shares outstanding on October 1, 2026 could be joined by 11,406,235 conversion shares, representing 83.3 percent of post-conversion common stock under the stated assumptions.

That outcome is not automatic for every holder because the 19.99 percent ownership cap can defer shares, and the final number can change with additional issuance. The filing nevertheless warns that the conversion may reduce ownership and voting power for shareholders who do not receive the preferred dividend.

Biotechnology profile and trading venue

Jaguar Health develops plant-derived prescription medicines for gastrointestinal diseases, including crofelemer programs for rare intestinal failure conditions. Its common stock trades on the Nasdaq Stock Market under JAGX, while the Series R preferred stock is not intended to receive a separate exchange listing, according to StockTitan.

Dates set the next decision points

The October 15, 2026 payment date comes first, followed by the November 2, 2026 conversion date. The company's release also points to a planned New Drug Application filing for crofelemer in microvillus inclusion disease in mid-2027, leaving the near-term shareholder distribution and the longer clinical timetable closely connected.